Vimarsana
Biggest News Aggregation in the World

Page 7 - Amy Wolf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Amy Wolf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Amy Wolf Today - Breaking & Trending Today

Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders' Meeting on 31 May 2023 - Vimarsana News

Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders' Meeting on 31 May 2023

REGULATED INFORMATION  Description of the regulatory framework of the share repurchase programproposed by the Board of Directors to be approved at theCombined Shareholders’ Meeting... | May 31, 2023

Ipsen S.A. - Combined Shareholders' Meeting of Ipsen S.A. held on 31 May 2023 - Vimarsana News

Ipsen S.A. - Combined Shareholders' Meeting of Ipsen S.A. held on 31 May 2023

REGULATED INFORMATION  COMBINED SHAREHOLDERS’ MEETING OF IPSEN S.A.HELD ON 31 MAY 2023 ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS’ VOTE HAVE BEEN APPROVED Paris , 31 May... | May 31, 2023

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U. - Vimarsana News

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva , an ultra-rare disease with an estimated prevalence of 1.36 per million... | May 26, 2023

Ipsen Pharma: Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U. - Vimarsana News

Ipsen Pharma: Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.

Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases - Vimarsana News

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

Six abstracts to be presented demonstrating efficacy and tolerability of investigational Bylvay in select cholestatic liver diseasesNew data emphasizes the consistent benefit of Bylvay as an... | May 17, 2023